EcoDrugPlus

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSSTUG00000045818
Gene Symbol: HTR1E
1 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSSTUG00000010903
Gene Symbol: HTR1F
3 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSTUG00000036075
Gene Symbol: HTR2A
3 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSTUG00000009968
Gene Symbol: HTR2A
3 Cross references
213 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b-Like

Ensembl ID : ENSSTUG00000026892
Gene Symbol: LOC115157961
3 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b-Like

Ensembl ID : ENSSTUG00000016716
Gene Symbol: LOC115151518
3 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSSTUG00000002127
Gene Symbol: LOC115195000
3 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSSTUG00000018078
Gene Symbol: LOC115204479
2 Cross references
149 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSSTUG00000036353
Gene Symbol: LOC115154864
2 Cross references
148 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSSTUG00000035330
Gene Symbol: LOC115198605
3 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSTUG00000019778
Gene Symbol: HTR3A
3 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSSTUG00000014106
Gene Symbol: HTR3B
3 Cross references
168 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).